Daxor (DXR) Competitors

Daxor (NASDAQ:DXR) and Profound Medical (NASDAQ:PROF) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, community ranking, dividends, analyst recommendations and institutional ownership.

Is DXR or PROF more profitable?

Daxor has a net margin of 0.00% compared to Profound Medical's net margin of -349.41%. Daxor's return on equity of 0.00% beat Profound Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Daxor	N/A	N/A	N/A
Profound Medical	-349.41%	-85.22%	-64.87%

Does the MarketBeat Community believe in DXR or PROF?

Profound Medical received 38 more outperform votes than Daxor when rated by MarketBeat users. However, 100.00% of users gave Daxor an outperform vote while only 72.73% of users gave Profound Medical an outperform vote.

Company	Underperform	Outperform
Daxor	Outperform Votes 2 100.00%	Underperform Votes No Votes
Profound Medical	Outperform Votes 40 72.73%	Underperform Votes 15 27.27%

Which has stronger earnings & valuation, DXR or PROF?

Daxor has higher earnings, but lower revenue than Profound Medical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Daxor	$2.13M	16.80	N/A	N/A	N/A
Profound Medical	$10.68M	13.32	-$28.57M	-$1.12	-4.23

Does the media prefer DXR or PROF?

In the previous week, Daxor had 4 more articles in the media than Profound Medical. MarketBeat recorded 8 mentions for Daxor and 4 mentions for Profound Medical. Daxor's average media sentiment score of 0.60 beat Profound Medical's score of 0.44 indicating that Daxor is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Daxor	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Profound Medical	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts recommend DXR or PROF?

Daxor currently has a consensus target price of $25.00, indicating a potential upside of 237.84%. Profound Medical has a consensus target price of $14.25, indicating a potential upside of 201.01%. Given Daxor's higher probable upside, equities research analysts clearly believe Daxor is more favorable than Profound Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daxor	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Profound Medical	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33

Do insiders and institutionals hold more shares of DXR or PROF?

1.3% of Daxor shares are held by institutional investors. Comparatively, 47.9% of Profound Medical shares are held by institutional investors. 59.0% of Daxor shares are held by insiders. Comparatively, 1.5% of Profound Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Which has more volatility and risk, DXR or PROF?

Daxor has a beta of -0.06, meaning that its stock price is 106% less volatile than the S&P 500. Comparatively, Profound Medical has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500.

Summary

Daxor beats Profound Medical on 9 of the 16 factors compared between the two stocks.